Clin2
NCT06380816Possibly a fitRecruiting

Study of UCB4594 for advanced cancers with HLA-G marker

Advanced Solid TumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal NeoplasmsTriple Negative Breast NeoplasmsCarcinoma, Renal Cell (Clear Cell Only)Esophageal NeoplasmsStomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)

Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
167 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have one of these cancers: head/neck, lung, colorectal, triple-negative breast, kidney (clear cell), stomach/esophageal, cervical, ovarian, or pancreatic cancer – and standard treatments no longer work or are not right for you.
  • You are willing to have a tumor biopsy (a small sample taken) before and possibly during treatment.
  • You must be able to do your daily activities with little or no help (ECOG 0-1) and have a life expectancy of at least 12 weeks.
  • You haven't had cancer treatment (chemo, radiation, immunotherapy) in the last 4 weeks, and any side effects from previous treatments are mild (except hair loss).
  • You do not have untreated or worsening brain metastases, active autoimmune disease, serious heart/lung conditions, or active infections like hepatitis or HIV.
  • If you can become pregnant, you must use highly effective birth control during and for several months after treatment.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06242470Recruiting· Phase 1
Study of MGC026 for advanced solid tumors

This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.

Los Angeles, California
NCT07090499Recruiting· Phase 1
Study of PF-08046876 for advanced solid tumors

This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.

Duarte, California
NCT06992687Enrolling by invitation· Phase 1/Phase 2
Study of HB0052 for advanced solid tumors

This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.

Beijing
NCT06245122Recruiting· Phase 1
Study of CS23546 for advanced tumors

This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.

Guangzhou
NCT07680569Not yet recruiting· Phase 1/Phase 2
HCB101 plus other drugs for advanced stomach cancer

This trial tests a new drug, HCB101, combined with other treatments for advanced stomach or gastroesophageal cancer. It may be an option if your tumor has a specific marker called CLDN18.2 and you haven't had prior systemic therapy.

NCT06803680Recruiting· Phase 1
Study of BGB-B455 for advanced solid tumors

This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.

Celebration, Florida

Hear when a new Carcinoma, Non-Small-Cell Lung trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.